These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34348262)

  • 1. Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan.
    Osawa L; Nakanishi H; Kurosaki M; Kirino S; Inada K; Yamashita K; Hayakawa Y; Sekiguchi S; Wang W; Okada M; Higuchi M; Komiyama Y; Takaura K; Takada H; Kaneko S; Maeyashiki C; Tamaki N; Yasui Y; Tsuchiya K; Itakura J; Takahashi Y; Enomoto N; Izumi N
    Dig Dis; 2022; 40(4):479-488. PubMed ID: 34348262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study.
    Suzuki Y; Naganuma A; Hoshino T; Hatanaka T; Ueno T; Namikawa M; Takizawa D; Arai H; Suzuki H; Takagi H; Tojima H; Yamazaki Y; Sato K; Kakizaki S; Uraoka T
    Acta Gastroenterol Belg; 2021; 84(1):57-63. PubMed ID: 33639694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.
    Yamada T; Ohki T; Hayata Y; Karasawa Y; Kawamura S; Ito D; Kojima K; Seki M; Toda N; Tagawa K
    Clin Drug Investig; 2016 Oct; 36(10):829-35. PubMed ID: 27405984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites.
    Hiramine Y; Uto H; Mawatari S; Kanmura S; Imamura Y; Hiwaki T; Saishoji A; Oku M; Tokushige K; Maenohara S; Ido A
    J Gastroenterol; 2021 Jan; 56(1):54-66. PubMed ID: 32959093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.
    Arase Y; Kagawa T; Tsuruya K; Sato H; Teramura E; Anzai K; Hirose S; Deguchi R; Shiraishi K; Mine T
    Clin Drug Investig; 2019 Jan; 39(1):45-54. PubMed ID: 30284699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    Iwamoto T; Maeda M; Saeki I; Hidaka I; Tajima K; Ishikawa T; Takami T; Sakaida I
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1231-1235. PubMed ID: 30370940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver.
    Wernze H; Spech HJ; Müller G
    Klin Wochenschr; 1978 Apr; 56(8):389-97. PubMed ID: 642412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
    Miyazaki M; Yada M; Tanaka K; Senjyu T; Goya T; Motomura K; Kohjima M; Kato M; Masumoto A; Kotoh K
    World J Gastroenterol; 2017 Aug; 23(29):5379-5385. PubMed ID: 28839438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.
    Arroyo V; Bosch J; Casamitjana R; Cabrera J; Rivera F; Rodés J
    Gut; 1980 Oct; 21(10):855-9. PubMed ID: 7439805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased renin release by exogenous prostaglandin E1 in liver cirrhosis with and without ascites.
    Uemasu J; Kawasaki H; Hirayama C
    Horm Metab Res; 1988 May; 20(5):302-5. PubMed ID: 3042580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.